Nutriband Stock News

ORLANDO, Fla., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO, Gareth Sheridan will attend the inaugural Nasdaq LaB Biotech Summit on September 16th.

Nutriband has received a Notice of Publication from the United States Patent and Trademark Office (USPTO) for commercial brand name trademarks for its lead product, an abuse deterrent fentanyl transdermal system. Once allowed, Nutriband plans to submit its commercial worldwide brand name to the FDA and other international regulatory agencies for approval.

Nutriband's Active Intelligence subsidiary to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference Company to Meet with Buyers from Walmart Inc, Walgreens, Amazon.com, Inc., Cardinal Health and Other Major National Retailers ORLANDO, Fla., May 15, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) and its wholly owned subsidiary Acti...

ORLANDO, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO and Co-Founder, Gareth Sheridan has featured on the latest episode of the Jack Neel Podcast to discuss the opioid crisis, the Company's AVERSA technology and the opportunity for Nutriband to improve the safety profile of easily abused medications.

Nutriband has selected the commercial worldwide brand name for its lead product, an abuse deterrent fentanyl transdermal system, and will submit to the FDA for approval per FDA Guidance. Nutriband partnered with Brand Institute, Inc, the global leader in pharmaceutical and healthcare-related brand name and identity development.